Načítá se...
Cost per responder of TNF-α therapies in Germany
Tumor necrosis factor α (TNF-α) inhibitors ranked highest in German pharmaceutical expenditure in 2011. Their most important application is the treatment of rheumatoid arthritis (RA). Our objective is to analyze cost per responder of TNF-α inhibitors for RA from the German Statutory Health Insurance...
Uloženo v:
| Vydáno v: | Clin Rheumatol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer London
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544564/ https://ncbi.nlm.nih.gov/pubmed/23877487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10067-013-2332-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|